10.22376/ijpbs.2019.10.1.p1-12 Volume 5 Issue 1 2014 (January - March) Metformin belongs to biguanides, Glimepiride is a second-generation sulfonylurea, Pioglitazone belongs to thiazolidinediones type of oral hypoglycaemic drugs. A prospective randomized open labelled parallel study was conducted in Type II Diabetes Mellitus patients. One group received Metformin and Glimepiride (M+G) where as another group received Metformin, Glimepiride and Pioglitazone (M+G+P) for 12 weeks. Baseline investigations were carried out before and after the study. The data was statistically analysed using students 'T' test. M+G+P group showed a significant fall (p lessThan 0.05) in fasting and post prandial blood glucose , giycosylated haemoglobin (p lessThan 0.05), significant rise ( p lessThan 0.05) in high density lipoprotein, better patient compliance and follow up compared to M+G group. There was no significant difference in triglycerides, low density lipoprotein levels in both the groups. Gastrointestinal side effects were more in M+G group while pedal oedema, hypoglycaemic episodes were more in M+G+P group. CH.V.NAGANJANI AND V. SUSMITHA Metformin, Glimepiride, Pioglitazone, blood glucose, Giycosylated haemoglobin, High density lipoprotein. 212-218